L1CAM expression in endometrial carcinomas: an ENITEC collaboration study

Thumbnail
View/Open
Issue date
2016
Author
van der Putten, Louis J. M.
Visser, Nicole C.M.
van de Vijver, Koen
Santacana, Maria
Bronsert, Peter
Bulten, Johan
Hirschfeld, Marc
Colás, Eva
Gil-Moreno, Antonio
Garcia, Angel
Mancebo, Gemma
Alameda, Fransesc
Trovik, Jone
Kopperud, Reidun K.
Huvila, Jutta
Schrauwen, Stefanie
Koskas, Martin
Walker, Francine
Weinberger, Vit
Minar, Lubos
Jandakova, Eva
Snijders, Marc P. L. M.
van den Berg-van Erp, Saskia
Matias-Guiu, Xavier
Salvesen, Helga B.
Amant, Frederic
Massuger, Leon F. A. G.
Pijnenborg, Johanna M. A.
Suggested citation
van der Putten, Louis J. M.; Visser, Nicole C.M.; van de Vijver, Koen; Santacana, Maria; Bronsert, Peter; Bulten, Johan; ... Pijnenborg, Johanna M. A.. (2016) . L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. British Journal of Cancer, 2016, vol. 115, núm. 6, p. 716-724. https://doi.org/10.1038/bjc.2016.235.
Impact

Google Scholar logo  Google Scholar
Share
Export to Mendeley
Metadata
Show full item record
Abstract
Background: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a clinically representative cohort of endometrial carcinomas. Methods: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive when 410% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological characteristics and disease outcome was calculated. Results: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the NEECs. Conclusions: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied.
URI
http://hdl.handle.net/10459.1/70910
DOI
https://doi.org/10.1038/bjc.2016.235
Is part of
British Journal of Cancer, 2016, vol. 115, núm. 6, p. 716-724
Collections

The following license files are associated with this item:

cc-by-nc-sa (c) van der Putten et al., 2016
Except where otherwise noted, this item's license is described as cc-by-nc-sa (c) van der Putten et al., 2016